Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -43.31% | 204.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.74% | 155.53% | |||
| Operating Income | 42.74% | -155.53% | |||
| Income Before Tax | 35.30% | -153.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.30% | -153.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.30% | -153.17% | |||
| EBIT | 42.74% | -155.53% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 50.00% | -100.00% | |||
| Normalized Basic EPS | 0.00% | -- | |||
| EPS Diluted | 50.00% | 88.89% | |||
| Normalized Diluted EPS | 0.00% | -- | |||
| Average Basic Shares Outstanding | 0.00% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
